Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

ALS is a progressive neurodegenerative disease that currently has no cure. Commonly known as Lou Gehrig’s disease, ALS ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease.

In this section you'll find photographic features that explore holidays and photography courses, details about members meetings, trials and tribulations of installing new software along with ...